Interleukin Inhibitors Market Report 2025

This Interleukin Inhibitors market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The interleukin inhibitors market size has grown rapidly in recent years. It will grow from $42.93 billion in 2024 to $49.84 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, increasing awareness of interleukin inhibitors, growing demand for personalized medicine, growing elderly population, and growing popularity of biosimilars.

The interleukin inhibitors market size is expected to see rapid growth in the next few years. It will grow to $96.66 billion in 2029 at a compound annual growth rate (CAGR) of 18%. The growth in the forecast period can be attributed to emerging therapeutic indications, the global aging population, immunotherapy combinations, and increasing investment in research and development. Major trends in the forecast period include oral interleukin inhibitors, next-generation therapies, pediatric indications, expanded access, and patient-centric care.

The burgeoning development of investigational drugs for inflammatory diseases like psoriasis, arthritis, and inflammatory bowel disease is set to propel the interleukin inhibitors market. These inhibitors curtail the actions of inflammatory cytokines, preserving tissue equilibrium and preventing harm to the host's immune responses. Presently, 48 molecules are under scrutiny for treating inflammatory conditions, with 20 in Phase III clinical trials. Upon approval, this robust pipeline is expected to drive the interleukin inhibitors market.

The increasing incidence of bacterial infections is anticipated to propel the growth of the interleukin inhibitors market in the coming years. Bacterial infections, caused by microscopic single-celled organisms, pose significant health challenges. Interleukin inhibitors play a crucial role in treating and preventing bacterial diseases by inhibiting bacterial growth. For example, in March 2024, the Centers for Disease Control and Prevention, a U.S.-based government agency, reported that tuberculosis cases surged from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Therefore, the rising prevalence of bacterial infections is significantly contributing to the expansion of the interleukin inhibitors market.

The expiration of patents for biologic drugs creates pathways for biosimilars, presenting a more cost-effective alternative. Major players in the interleukin sector concentrate on biosimilar development for inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), pursued by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions. Despite the clinical advantages, limited patient access to biological therapy, primarily due to elevated treatment costs, drives the biosimilars trend. Rapid advancements in biotechnology and analytical sciences ensure biosimilar comparability to biological drugs, further bolstering this trend.

Leading market players are securing regulatory nods for novel antibiotic formulations. For instance, Risankizumab-rzaa, an FDA-approved interleukin-23 (IL-23) inhibitor, gained approval in June 2022 for treating adults with moderately to severely active Crohn's disease (CD). These drugs target specific cytokines and immune pathways, mitigating inflammation and enhancing patient outcomes, showcasing the market's commitment to innovative pharmaceuticals.

Major companies operating in the interleukin inhibitors market include Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Seattle Genetics Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.

Interleukin inhibitors are substances utilized to dampen the immune system's activity by impeding the function of interleukins. Interleukins belong to a group of cytokines produced by white blood cells (lymphocytes, monocytes, and macrophages) in response to infections, playing a vital role in immune system regulation.

The primary types of interleukin inhibitors encompass IL-17, IL-23, IL-1, IL-5, IL-6, among others. Interleukin 17, a pro-inflammatory cytokine from the cystine knot family, is produced by a specific subset of T helper cells called T helper 17 cells upon stimulation by IL-23. These inhibitors find application in treating conditions like psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and more. They are distributed through various channels, including hospital pharmacies, retail outlets, and online pharmacies.

The interleukin inhibitors market research report is one of a series of new reports that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.'

North America was the largest region in the interleukin inhibitors market in 2024. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.